Cancer Research CTRC-AACR San Antonio Breast Cancer Symposium Susan G. Komen for the Cure-AACR Outstanding Investigator Award for Breast Cancer Research
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation
[Cancer Research 59, 5429-5432, November 1, 1999]
© 1999 American Association for Cancer Research
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Carpentier, A. F.
Right arrow Articles by Delattre, J.-Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Carpentier, A. F.
Right arrow Articles by Delattre, J.-Y.
[Cancer Research 59, 5429-5432, November 1, 1999]
© 1999 American Association for Cancer Research

Advances in Brief

Oligodeoxynucleotides Containing CpG Motifs Can Induce Rejection of a Neuroblastoma in Mice1

Antoine F. Carpentier2, Lin Chen, Fabrice Maltonti and Jean-Yves Delattre

Fédération de neurologie Mazarin et INSERM U 495, Hôpital de la Pitié-Salpêtrière, 75013 Paris, France [A.F.C., F.M., J-Y.D.], and UPRES 264, Université Paris VI, Hôpital Broussais, 75014 Paris, France [L.C.]

Phosphorothioate oligodeoxynucleotides with CpG motifs (CpG-ODNs) activate various immune cell subsets and induce production of numerous cytokines. To evaluate whether CpG-ODNs can induce rejection of established malignant tumor, A/J mice were challenged by the s.c. implantation of a syngenic neuroblastoma cell line (neuro2a) and subsequently injected with CpG-ODNs in the vicinity of the tumor. Daily injections of 10 µg CpG-ODNs for 15 days seemed to be the most potent regimen, leading to the eradication of 5-mm-diameter tumors in one-half of the animals and a significant tumor growth inhibition when compared with controls (88% reduction volume; P < 0.001). CpG-ODN-cured animals were further protected against a new tumor challenge. The antitumoral effect of CpG-ODNs was dependent on CpG motifs, and natural killer cells seemed to play a critical role in tumor rejection. We conclude that immunostimulatory CpG-ODNs may induce the rejection of established tumors and warrant further evaluation as a potential immunotherapeutic agent.




This article has been cited by other articles:


Home page
 J. Leukoc. Biol.Home page
R. B. Anderson, G. J. Cianciolo, M. N. Kennedy, and S. V. Pizzo
{alpha}2-Macroglobulin binds CpG oligodeoxynucleotides and enhances their immunostimulatory properties by a receptor-dependent mechanism
J. Leukoc. Biol., February 1, 2008; 83(2): 381 - 392.
[Abstract] [Full Text] [PDF]

Home page
 Neuro OncolHome page
A. Carpentier, F. Laigle-Donadey, S. Zohar, L. Capelle, A. Behin, A. Tibi, N. Martin-Duverneuil, M. Sanson, L. Lacomblez, S. Taillibert, et al.
Phase 1 trial of a CpG oligodeoxynucleotide for patients with recurrent glioblastoma
Neuro-oncol, January 1, 2006; 8(1): 60 - 66.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
L. Chaperot, A. Blum, O. Manches, G. Lui, J. Angel, J.-P. Molens, and J. Plumas
Virus or TLR Agonists Induce TRAIL-Mediated Cytotoxic Activity of Plasmacytoid Dendritic Cells
J. Immunol., January 1, 2006; 176(1): 248 - 255.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
C. Brignole, F. Pastorino, D. Marimpietri, G. Pagnan, A. Pistorio, T. M. Allen, V. Pistoia, and M. Ponzoni
Immune Cell-Mediated Antitumor Activities of GD2-Targeted Liposomal c-myb Antisense Oligonucleotides Containing CpG Motifs
J Natl Cancer Inst, August 4, 2004; 96(15): 1171 - 1180.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
P. Daftarian, G.-Y. Song, S. Ali, M. Faynsod, J. Longmate, D. J. Diamond, and J. D. I. Ellenhorn
Two Distinct Pathways of Immuno-Modulation Improve Potency of p53 Immunization in Rejecting Established Tumors
Cancer Res., August 1, 2004; 64(15): 5407 - 5414.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
T. Switaj, A. Jalili, A. B. Jakubowska, N. Drela, M. Stoksik, D. Nowis, G. Basak, J. Golab, P. J. Wysocki, A. Mackiewicz, et al.
CpG Immunostimulatory Oligodeoxynucleotide 1826 Enhances Antitumor Effect of Interleukin 12 Gene-Modified Tumor Vaccine in a Melanoma Model in Mice
Clin. Cancer Res., June 15, 2004; 10(12): 4165 - 4175.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
N. Garbi, B. Arnold, S. Gordon, G. J. Hammerling, and R. Ganss
CpG Motifs as Proinflammatory Factors Render Autochthonous Tumors Permissive for Infiltration and Destruction
J. Immunol., May 15, 2004; 172(10): 5861 - 5869.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
A. S. Lonsdorf, H. Kuekrek, B. V. Stern, B. O. Boehm, P. V. Lehmann, and M. Tary-Lehmann
Intratumor CpG-Oligodeoxynucleotide Injection Induces Protective Antitumor T Cell Immunity
J. Immunol., October 15, 2003; 171(8): 3941 - 3946.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
E. Hartmann, B. Wollenberg, S. Rothenfusser, M. Wagner, D. Wellisch, B. Mack, T. Giese, O. Gires, S. Endres, and G. Hartmann
Identification and Functional Analysis of Tumor-Infiltrating Plasmacytoid Dendritic Cells in Head and Neck Cancer
Cancer Res., October 1, 2003; 63(19): 6478 - 6487.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
F. Elias, J. Flo, R. A. Lopez, J. Zorzopulos, A. Montaner, and J. M. Rodriguez
Strong Cytosine-Guanosine-Independent Immunostimulation in Humans and Other Primates by Synthetic Oligodeoxynucleotides with PyNTTTTGT Motifs
J. Immunol., October 1, 2003; 171(7): 3697 - 3704.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
H. H. van Ojik, L. Bevaart, C. E. Dahle, A. Bakker, M. J. H. Jansen, M. J. van Vugt, J. G. J. van de Winkel, and G. J. Weiner
CpG-A and B Oligodeoxynucleotides Enhance the Efficacy of Antibody Therapy by Activating Different Effector Cell Populations
Cancer Res., September 1, 2003; 63(17): 5595 - 5600.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
B. J. Weigel, D. A. Rodeberg, A. M. Krieg, and B. R. Blazar
CpG Oligodeoxynucleotides Potentiate the Antitumor Effects of Chemotherapy or Tumor Resection in an Orthotopic Murine Model of Rhabdomyosarcoma
Clin. Cancer Res., August 1, 2003; 9(8): 3105 - 3114.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
Y.-L. Chen, S.-H. Chen, J.-Y. Wang, and B.-C. Yang
Fas Ligand on Tumor Cells Mediates Inactivation of Neutrophils
J. Immunol., August 1, 2003; 171(3): 1183 - 1191.
[Abstract] [Full Text] [PDF]

Home page
 Int ImmunolHome page
Y. Wang and A. M. Krieg
Synergy between CpG- or non-CpG DNA and specific antigen for B cell activation
Int. Immunol., February 1, 2003; 15(2): 223 - 231.
[Abstract] [Full Text] [PDF]

Home page
 FASEB J.Home page
L. SFONDRINI, D. BESUSSO, C. RUMIO, M. RODOLFO, S. MENARD, and A. BALSARI
Prevention of spontaneous mammary adenocarcinoma in HER-2/neu transgenic mice by foreign DNA
FASEB J, November 1, 2002; 16(13): 1749 - 1754.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
K. Heckelsmiller, K. Rall, S. Beck, A. Schlamp, J. Seiderer, B. Jahrsdorfer, A. Krug, S. Rothenfusser, S. Endres, and G. Hartmann
Peritumoral CpG DNA Elicits a Coordinated Response of CD8 T Cells and Innate Effectors to Cure Established Tumors in a Murine Colon Carcinoma Model
J. Immunol., October 1, 2002; 169(7): 3892 - 3899.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
I. Espinoza-Delgado
Cancer Vaccines
Oncologist, August 1, 2002; 7(90003): 20 - 33.
[Abstract] [Full Text] [PDF]

Home page
 J. Leukoc. Biol.Home page
B. Jahrsdorfer, R. Jox, L. Muhlenhoff, K. Tschoep, A. Krug, S. Rothenfusser, G. Meinhardt, B. Emmerich, S. Endres, and G. Hartmann
Modulation of malignant B cell activation and apoptosis by bcl-2 antisense ODN and immunostimulatory CpG ODN
J. Leukoc. Biol., July 1, 2002; 72(1): 83 - 92.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
L. Sfondrini, D. Besusso, M. T. Zoia, M. Rodolfo, A. M. Invernizzi, M. Taniguchi, T. Nakayama, M. P. Colombo, S. Menard, and A. Balsari
Absence of the CD1 Molecule Up-Regulates Antitumor Activity Induced by CpG Oligodeoxynucleotides in Mice
J. Immunol., July 1, 2002; 169(1): 151 - 158.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
T. Decker, S. Hipp, R. J. Kreitman, I. Pastan, C. Peschel, and T. Licht
Sensitization of B-cell chronic lymphocytic leukemia cells to recombinant immunotoxin by immunostimulatory phosphorothioate oligodeoxynucleotides
Blood, February 15, 2002; 99(4): 1320 - 1326.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
Z. K. Ballas, A. M. Krieg, T. Warren, W. Rasmussen, H. L. Davis, M. Waldschmidt, and G. J. Weiner
Divergent Therapeutic and Immunologic Effects of Oligodeoxynucleotides with Distinct CpG Motifs
J. Immunol., November 1, 2001; 167(9): 4878 - 4886.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
Y. Kawarada, R. Ganss, N. Garbi, T. Sacher, B. Arnold, and G. J. Hammerling
NK- and CD8+ T Cell-Mediated Eradication of Established Tumors by Peritumoral Injection of CpG-Containing Oligodeoxynucleotides
J. Immunol., November 1, 2001; 167(9): 5247 - 5253.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
G. Auf, A. F. Carpentier, L. Chen, C. Le Clanche, and J.-Y. Delattre
Implication of Macrophages in Tumor Rejection Induced by CpG-oligodeoxynucleotides Without Antigen
Clin. Cancer Res., November 1, 2001; 7(11): 3540 - 3543.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
K. H. Baek, S. J. Ha, and Y. C. Sung
A Novel Function of Phosphorothioate Oligodeoxynucleotides as Chemoattractants for Primary Macrophages
J. Immunol., September 1, 2001; 167(5): 2847 - 2854.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
B. R. Blazar, A. M. Krieg, and P. A. Taylor
Synthetic unmethylated cytosine-phosphate-guanosine oligodeoxynucleotides are potent stimulators of antileukemia responses in naive and bone marrow transplant recipients
Blood, August 15, 2001; 98(4): 1217 - 1225.
[Abstract] [Full Text] [PDF]

Home page
 J. Leukoc. Biol.Home page
G. J. Weiner
The immunobiology and clinical potential of immunostimulatory CpG oligodeoxynucleotides
J. Leukoc. Biol., October 1, 2000; 68(4): 455 - 463.
[Abstract] [Full Text]

Home page
 J. Immunol.Home page
S. W. Lee, M. K. Song, K. H. Baek, Y. Park, J. K. Kim, C. H. Lee, H.-K. Cheong, C. Cheong, and Y. C. Sung
Effects of a Hexameric Deoxyriboguanosine Run Conjugation into CpG Oligodeoxynucleotides on Their Immunostimulatory Potentials
J. Immunol., October 1, 2000; 165(7): 3631 - 3639.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. Lanuti, S. Rudginsky, S. D. Force, E. S. Lambright, W. M. Siders, M. Y. Chang, K. M. Amin, L. R. Kaiser, R. K. Scheule, and S. M. Albelda
Cationic Lipid:Bacterial DNA Complexes Elicit Adaptive Cellular Immunity in Murine Intraperitoneal Tumor Models
Cancer Res., June 1, 2000; 60(11): 2955 - 2963.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. F. Carpentier, J. Xie, K. Mokhtari, and J.-Y. Delattre
Successful Treatment of Intracranial Gliomas in Rat by Oligodeoxynucleotides Containing CpG Motifs
Clin. Cancer Res., June 1, 2000; 6(6): 2469 - 2473.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation
Copyright © 1999 by the American Association for Cancer Research.